The Regional Cancer Centre at Thiruvananthapuram is a cancer care hospital and research centre. RCC was established in 1981 by the Government of Kerala and the Government of India. It is located in the Thiruvananthapuram Medical College campus in Thiruvananthapuram, the capital city of the state of Kerala.

During the past decade, Regional Cancer Centre conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 3 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 9 clinical trials started and 3 clinical trials were completed. i.e. 33.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Regional Cancer Centre" #1 sponsor was "Eli Lilly and Company" with 4 trials, followed by "Bayer" with 2 trials sponsored, "Karyopharm Therapeutics Inc" with 2 trials sponsored, "Loxo Oncology, Inc." with 2 trials sponsored and "Cadila Pharnmaceuticals" with 2 trials sponsored. Other sponsors include 6 different institutions and companies that sponsored additional 16 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Regional Cancer Centre" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator, "Eisai Europe Ltd. (United Kingdom)" with 1 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 1 trials as a collaborator, "Ministry of Science and Technology, India" with 1 trials as a collaborator and "NSABP Foundation Inc" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 6 trials.

According to Clinical.Site data, the most researched conditions in "Regional Cancer Centre" are "Breast Neoplasms" (3 trials), "Carcinoma, Non-Small-Cell Lung" (2 trials), "Head and Neck Cancer" (2 trials), "Neoplasm Metastasis" (2 trials) and "Acute Promyelocytic Leukemia" (1 trials). Many other conditions were trialed in "Regional Cancer Centre" in a lesser frequency.

Most popular intervention types in "Regional Cancer Centre" are "Drug" (21 trials), "Biological" (3 trials), "Other" (2 trials), "Dietary Supplement" (1 trials) and "Radiation" (1 trials). Other intervention types were less common.

The name of intervention was led by "Abemaciclib" (3 trials), "Placebo" (3 trials), "Darolutamide (Nubeqa, BAY1841788)" (2 trials), "Docetaxel" (2 trials) and "Exemestane" (2 trials). Other intervention names were less common.

The vast majority of trials in "Regional Cancer Centre" are 17 trials for "All" genders, 3 trials for "Male" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "Regional Cancer Centre". undefined are not yet recruiting, 8 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 5 completed trials in Regional Cancer Centre, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in Regional Cancer Centre, 0 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 13 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 0 trials that are defined as “Not Applicable".